You searched for "Retinal"

3638 results found

Vision loss during Eylea treatment for AMD

This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....

Vitreoretinal Disease: Diagnosis, Management and Clinical Pearls (second edition)

A comprehensive, well-illustrated and highly informative resource providing excellent descriptions of vitreoretinal diseases, their presentation, diagnosis and management. The 40 chapters are grouped into four sections, namely: the Anatomy and Physiology of the vitreous, retina, choroid and retinal pigment epithelium;...

The blue-light hazard – is it true?

Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: The blue-light hazard – is it true? Blue light is part of the visible optical spectrum...

RTP801 as a neuroprotective and axon regenerative treatment

This paper describes the neuroprotective and axon regenerative effects of siRTP801, which is a translatable small-interfering RNA (siRNA) targeting mTOR negative regulator; RTP801, through in-vivo and in-vitro models. In-vivo studies involved an optic nerve crush rat model with intravitreal injections...

SLT short-term results

The aim of the study was to evaluate the risk of adverse effects and short-term results after 360 degrees selective laser trabeculoplasty (SLT) in glaucoma patients. The authors enrolled 64 eyes of 64 patients all who had poorly controlled primary...

Management of a giant pigment epithelium detachment with transition from half- to full-dose aflibercept

This case report describes the management of a giant pigment epithelial detachment (PED) in neovascular age-related macular degeneration (nAMD) using half-dose aflibercept. An 80-year-old woman presented with a huge PED (maximum height 1338µm) and multiple risk factors for retinal pigment...

DR-NET National DR Workshop in Tanzania: Policy, training and technology

Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...

OCT changes in chronic optic neuropathy

The authors evaluated optical coherence tomography (OCT) angiography in 10 patients who suffered various types of chronic optic neuropathies. Glaucoma is known to cause a decrease in peripapillary perfused capillary density on OCT angiography. However, other optic neuropathies have not...

Cybersight: Using OCT as an Approach to Diagnose Glaucomatous and Other Optic Neuropathies

Clinically, the difference between glaucomatous and simple optic atrophy of other origins is not always clear. OCT with the ability to image and measure inner retinal layers in the macula and peripapillary area, with the measurement of rim atrophy, is...

Effect of laser wavelength on delivering effective burns through opaque lens using pattern scan laser

Panretinal photocoagulation (PRP) has been used in the treatment of various retinal disorders for many decades. Conventional single-spot lasers take quite some time to do with significantly higher pain, anxiety and photophobia when compared to the pattern scan laser (PSL)....

Using optical coherence tomography angiography to detect MoyaMoya vasculopathy

Moyamoya (MM) disease is a chronic cerebrovascular disease that can lead to progressive stenosis of the terminal portions of the internal carotid arteries and their proximal branches. The authors carried out a cross-sectional cohort study to investigate vascular changes in...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...